Trastuzumab deruxtecan vs standard care for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be a type called high-grade serous or high-grade endometrioid, and it must have come back after treatment.
- Your tumor must show at least some HER2 protein (scored 1+, 2+, or 3+) on a lab test.
- You must have had cancer progression while on a PARP inhibitor, and you must have taken that PARP inhibitor for at least 6 months with no progression before that.
- You need to have a tumor that can be measured on scans (RECIST 1.1 criteria).
- Your heart function (LVEF) must be at least 50%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding trastuzumab deruxtecan to standard maintenance therapy with bevacizumab works better than bevacizumab alone for people with advanced ovarian cancer that has the HER2 protein. It is for those who have finished initial chemotherapy plus bevacizumab and are now starting maintenance treatment.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial tests adding trastuzumab to standard maintenance therapy with bevacizumab for patients with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if the combination helps keep the cancer from growing longer.
This trial tests whether a targeted drug called trastuzumab deruxtecan can help people with advanced HER2-positive stomach, esophageal, or gastroesophageal junction cancer. It's for those who haven't had chemotherapy for metastatic disease and are not able to get combination therapy.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This trial tests a new drug called trastuzumab deruxtecan (a targeted antibody-drug combination) for people with advanced breast cancer that never showed any HER2 protein (HER2-zero). The goal is to see if it can shrink tumors and improve outcomes for those who have already had standard treatments.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.